Nerve growth factor antibody for the treatment of osteoarthritis pain and chronic low-back pain: mechanism of action in the context of efficacy and safety
Martin Schmelz(Heidelberg University), Lars Viktrup(Eli Lilly (United States)), Anne‐Marie Malfait(Rush University Medical Center), Tony L. Yaksh(University of California San Diego), John T. Farrar(University of Pennsylvania), Patrick W. Mantyh(University of Arizona), Leslie Tive(Pfizer (United States))
Cited by 141
Related Papers
Effects of Testosterone Treatment in Older Men
|New England Journal of Medicine|2016|864
Clinical Classification of Itch: a Position Paper of the International Forum for the Study of Itch
|Acta Dermato Venereologica|2007|748
The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis
|Proceedings of the National Academy of Sciences|2000|662
Aggrecan degradation in human articular cartilage explants is mediated by both ADAMTS‐4 and ADAMTS‐5
|Arthritis & Rheumatism|2007|403
The role of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) in a model of cartilage degradation
|Osteoarthritis and Cartilage|2001|324